血清CA125、AFP、CEA、CA19-9联检对上皮性卵巢癌的临床诊断价值

目的探讨血清CA125、AFP、CEA、CA19-9联检对上皮性卵巢癌的临床诊断价值。方法收集2007年3月～2010年7月兰州大学第二医院行手术治疗的151例卵巢肿瘤患者的临床资料,对其进行回顾性分析。结果卵巢癌组血清CA125的含量明显高于卵巢良性肿瘤组;CA125、AFP、CEA、CA19-9联合检测对卵巢癌诊断的敏感性较单独检测高,特异性较单独检测低;CA125在浆液性囊腺癌患者血清中的浓度最高。结论 CA125对卵巢癌诊断的敏感性、特异性不高。联检有效地提高了对卵巢癌诊断的敏感性,但是其诊断卵巢癌的特异性较低。

Clinical Diagnosis Value of Combined Detection of Serum CA125,AFP,CEA and CA19-9 in Epithelial Ovarian Cancer

Objective To study the clinical diagnosis value of joint detection of serum CA125, AFP, CEA and CA19-9 in epithelial ovarian cancer. Methods The clinical data of 151 cases of ovarian tumors treated primarily in the Second Hospital of Lanzhou Uni- versity from March 2007 to July 2010 were collected and analyzed retrospectively. Results The serum CA125 level of the ovarian cancer group was significantly higher than that of the benign ovarian tumor group（P〈0.05）. In ovarian cancer, the sensitivity of the combined detection of CA125,AFP,CEA and CAt9-9 was higher than that of detection alone of CA125. CA125 was the highest in serious cystadenocarcinoma. Conclusion The sensitivity and specificity of CA125 to ovarian cancer are not high. The combined detec- tion may improve the sensitivity of its diagnosis,but its specificity is low.